Context Therapeutics Faces Nasdaq Delisting Notice as Stock Sinks Below $1.00
CNTX is trading near its 52-week low of $0.545 (10.0% above the low).
Summary
Context Therapeutics received a Nasdaq delisting notice after its stock price fell below $1.00 for 30 consecutive business days. The company has until January 25, 2027, to regain compliance or face delisting.
Key Events · Legal and Risk Events · CNTX
-
Nasdaq Delisting Notice Received
On July 29, 2026, Context Therapeutics received a Nasdaq delisting notice for failing to maintain a minimum closing bid price of $1.00 per share for 30 consecutive business days.
-
Compliance Deadline Set
The company has an initial 180-day period, until January 25, 2027, to regain compliance by achieving a closing bid price of at least $1.00 for 10 consecutive business days.
-
Potential Second Compliance Period
If the company fails to regain compliance by the initial deadline, it may be eligible for an additional 180-day period, provided it meets certain market value and listing standards and notifies Nasdaq of its intent to cure.
-
Delisting Risk if Compliance Not Achieved
If the company does not regain compliance within the allotted period(s), Nasdaq will issue a delisting notice, which the company may appeal to a Hearings Panel, though success is not assured.
Analysis · CNTX · Life Sciences
A Nasdaq delisting notice landed at Context Therapeutics on July 29, 2026, after its stock closed below $1.00 for 30 consecutive business days. The company now has until January 25, 2027, to regain compliance by sustaining a closing bid price of at least $1.00 for 10 consecutive business days. Should it fall short, delisting could follow, though a second 180-day window may open if certain conditions are satisfied. The notice arrives at a difficult moment: the company recently posted widening losses and accelerating cash burn, and despite encouraging Phase 1 data for its lead candidate CTIM-76, the stock has struggled to hold value. Immediate pressure is mounting to pursue a reverse stock split or other measures to lift the share price, actions that risk significant dilution or operational disruption.
At the time of this filing, CNTX was trading at $0.60 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $55.1M. The 52-week trading range was $0.55 to $3.62. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.